Abstract
Nanoparticles are currently being intensively studied for in vivo molecular imaging because of their unique and beneficial properties. Among these particles, some metal particles possess strong surface plasmon fields that can effectively alter fluorescence. Using this fluorescence alteration, an NIR fluorophore based, nanosized contrast agent for breast cancer diagnosis is being developed. The fluorophore is conjugated to gold nanoparticles (GNP) viaa short spacer whose lengthwas specially adjusted to have the strong plasmon field to quench the fluorescence. The spacer also has a special molecular sequence that can be cleaved by an enzyme secreted by targeted cancer cells. Normally, the entity does not fluoresce. If it is delivered to the cancer site, the short spacer would be cleaved by the enzyme secreted by the cancer cell at which point the fluorescence would be restored. This entity can incorporate a cancer targeting molecule for a cancer specific delivery. The entity specifically targets cancer cells and fluoresce only when the spacer is cleaved by a specific cancer secreting biomolecule, providing dual specificity for cancer diagnosis. In the future, this entity will be combined with cancer drugs for seamless detection and personalized therapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Singh R and Lillard JW (2009) Nanoparticle-based targeted drug delivery. Journal/Experimental and Molecular Pathology 102:38
Hong B and Kang KA (2006) Biocompatible, nanogold-particle fluorescence enhancer for fluorophore mediated, optical immunosensor. Journal/Biosensors and Bioelectronics 21:1333-1338
Hong B and Kang KA (2006) Fluorescence Enhancers for Fluorophore Mediated Biosensors forCardiovascularDiseaseDiagnosis. Journal/Advances in experimentalmedicine and biology 578:179-184
Anger P, Bharadwaj P and Novotny L (2006) Enhancement and quenching of single-molecule fluorescence. Journal/Physical review letters 96:113002
Bharadwaj P, Anger P and Novotny L (2007) Nanoplasmonic enhancement of single-molecule fluorescence. Journal/Nanotechnology 18:044017
Stranik O, McEvoy HM, McDonagh C and MacCraith BD (2005) Plasmonic enhancement of fluorescence for sensor application. Journal/Sensors and actuators B 107:148-153
Connor EE, Mwamuka J, Gole A, Murphy CJ and Wyatt MD (2005) Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Journal/Small 1:325-327
Achilefu S, Dorshow R, Bugaj J and Rajagopalan R (2000) Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. Journal/Invest Radiol 35:479-485
Pakneshan P, Szyf M, Farias-Eisner R and Rabbani S (2004) Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer gr. Journal/J Biol Chem 279:31735-44.
Merrifield RB (1963) Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Joural/J. Am. Chem. Soc. 84:2149-2154
Wang J, Nantz MH, Achilefu S and Kang KA (2008) FRET-Like Fluorophore-Nanoparticle Complex for Highly Specific Cancer Localization. Journal/Advances in experimental medicine and biology
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this paper
Cite this paper
Wang, J. et al. (2011). Highly Specific, NIR Fluorescent Contrast Agent with Emission Controlled by Gold Nanoparticle. In: LaManna, J., Puchowicz, M., Xu, K., Harrison, D., Bruley, D. (eds) Oxygen Transport to Tissue XXXII. Advances in Experimental Medicine and Biology, vol 701. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-7756-4_21
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7756-4_21
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-7755-7
Online ISBN: 978-1-4419-7756-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)